For the year ending 2025-12-31, LBRX had $227,467K increase in cash & cash equivalents over the period. -$35,260K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Total research and development expenses | 16,744 |
| General and administrative expenses | 13,660 |
| Total operating loss | 30,404 |
| Non-operating income | 5,200 |
| Income tax provision | 1 |
| Net loss | -25,205 |
| Stock-based compensation expense | 4,191 |
| Shares issued for services rendered | 0 |
| Loss on write off of property and equipment | 8 |
| Write off of deferred offering costs | 0 |
| Depreciation and amortization | 321 |
| Noncash lease expense | 147 |
| Realized gain on sale of marketable securities, net | 119 |
| Amortization (accretion) of premiums (discounts) on investments, net | -261 |
| (gain) loss on change in fair value of derivative instruments | 1,161 |
| Prepaid expenses and other current assets | 12,339 |
| Operating lease liability | -134 |
| Accrued interest on marketable securities | -268 |
| Accounts payable and accrued expenses | -910 |
| Net cash used in operating activities | -35,208 |
| Purchases of property and equipment | 52 |
| Purchase of marketable securities | 44,836 |
| Proceeds from the sale of marketable securities | 2,501 |
| Maturities of marketable securities | 2,500 |
| Net cash (used in) provided by investing activities | -39,887 |
| Proceeds from initial public offering | 327,750 |
| Payment of issuance costs for initial public offering | 25,435 |
| Proceeds from exercise of warrants and options | 247 |
| Proceeds from issuance of redeemable convertible series c preferred stock | 0 |
| Payment of issuance costs for redeemable convertible series c preferred stock | 0 |
| Net cash provided by financing activities | 302,562 |
| Net increase in cash, cash equivalents and restricted cash | 227,467 |
| Cash, cash equivalents and restricted cash, beginning of period | 23,476 |
| Cash, cash equivalents and restricted cash, end of period | 250,943 |
LB PHARMACEUTICALS INC (LBRX)
LB PHARMACEUTICALS INC (LBRX)